By Maxx Chatsko A recent acquisition could pair nicely with the commercial infrastructure being built for the recently-approved Opzelura. Poor old Incyte Corporation (INCY) – Get Incyte Corporation Report never seems to catch a break. The drug developer has tried and failed to diversify its product portfolio away from the blockbuster Jakafi over the years, but nearly every attempt has been accompanied by a high-profile failure. Shares have delivered a negative return in the last five years and have remained relatively flat for much of that span. The latest focus on treating vitiligo could fina…